Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Abstract

Bradykinin, through its B2 receptor, stimulates endothelial release of a number of vasodilators, such as nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). Angiotensin-converting enzyme (ACE) inhibitors enhance the effects of local bradykinin by decreasing its degradation and by increasing B2 receptor sensitivity. Clinical and experimental studies demonstrate that blockade of the B2 receptor attenuates the antihypertensive, antihypertrophic, and antiatherosclerotic effects of ACE inhibitors. Thus, the evidence strongly supports a role for bradykinin in mediating the cardiovascular benefits of ACE inhibitors.

ACE inhibitors, ramipril, bradykinin, endothelial dysfunction, kallikrein-kinin system, renin-angiotensin system

References

[1]

Ferreira
SH
, Bartelt DC, Greene LJ. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom.
Biochemistry
.
1970
;
9
:
2583
–2593

[2]

Ondetti
MA
, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jaracaca. Isolation, elucidation of structure, and synthesis.
Biochemistry
.
1971
;
10
:
4033
–4039

[3]

Erdös
EG
. The angiotensin I converting enzyme. Fed Proc. 1977. p. 1760–1765

[4]

Dzau
VJ
, Re R. Tissue angiotensin system in cardiovascular medicine — A paradigm shift.
Circulation
.
1994
;
89
:
493
–498

[5]

Røjkjær
R
, Schmaier AH. Activation of the plasma kallikrein/kinin system on endothelial cells. Proc Assoc Am Physicians. 1999. p. 220–227

[6]

Linz
W
, Wohlfart P, Schölkens BA, Malinski T, Wiemer G. Interactions among ACE, kinins and NO.
Cardiovasc Res
.
1999
;
43
:
549
–561

[7]

Brown
NJ
, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway.
Circulation
.
2000
;
102
:
2190
–2196

[8]

Skidgel
RA
, Erdös EG. Biochemistry of angiotensin I-converting enzyme. Robertson JIS, Nicholls MG. The Renin-Angiotensin System. New York: Raven Press, Ltd; 1993. p. 10.1–10.10

[9]

Timmermans
PB
, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists.
Pharmacol Rev
.
1993
;
45
:
205
–251

[10]

Berry
C
, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide.
Am J Physiol Heart Circ Physiol
.
2001
;
281
:
H2337
–H2365

[11]

Gohlke
P
, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism.
Hypertension
.
1998
;
31
:
349
–355

[12]

Kramar
EA
, Harding JW, Wright JW. Angiotensin II- and IV-induced changes in cerebral blood flow; Roles of AT1, AT2, and AT4 receptor subtypes.
Regul Peptides
.
1997
;
68
:
131
–138

[13]

Kerins
DM
, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.
J Clin Invest
.
1995
;
96
:
2515
–2520

[14]

Murphey
LJ
, Hachey DL, Oates JA, Morrow JD, Brown NJ. Metabolism of bradykinin in vivo in humans: Identification of BK1–5 as a stable plasma peptide metabolite.
J Pharmacol Exp Ther
.
2000
;
294
:
263
–269

[15]

Pellacani
A
, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects.
Clin Sci
.
1994
;
87
:
567
–574

[16]

Hecker
M
, Porsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level.
Br J Pharmacol
.
1994
;
111
:
238
–244

[17]

Hecker
M
, Blaukat A, Bara AT, Müller-Esterl W, Busse R. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
Br J Pharmacol
.
1997
;
121
:
1475
–1481

[18]

Benzing
T
, Fleming I, Blaukat A, Müller-Esterl W, Busse R. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native.
Circulation
.
1999
;
99
:
2034
–2040

[19]

Marcic
B
, Deddish PA, Jackman HL, Erdös EG. Enhancement of bradykinin and resensitization of its B2 receptor.
Hypertension
.
1999
;
33
:
835
–843

[20]

Carey
RM
, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function.
Hypertension
.
2000
;
35
:
155
–163

[21]

Cockcroft
JR
, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
J Cardiovasc Pharmacol
.
1993
;
22
:
579
–784

[22]

Hornig
B
, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.
Circulation
.
2001
;
103
:
799
–805

[23]

Linz
W
, Schölkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.
Br J Pharmacol
.
1992
;
105
:
771
–772

[24]

Bouaziz
H
, Joulin Y, Safar M, Benetos A. Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition.
Br J Pharmacol
.
1994
;
113
:
717
–722

[25]

Barbe
F
, Su JB, Guyene TT, Crozatier B, Menard J, Hittinger L. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure.
Am J Physiol
.
1996
;
270
:
H1985
–H1992

[26]

Brown
NJ
, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
J Pharmacol Exp Ther
.
1996
;
279
:
703
–712

[27]

Cockcroft
JR
, Chowrienczyk PJ, Brett SE, Bender N, Ritter JM. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.
Br J Clin Pharmacol
.
1994
;
38
:
317
–321

[28]

Hornig
B
, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.
Circulation
.
1997
;
95
:
1115
–1118

[29]

Gainer
JV
, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
N Engl J Med
.
1998
;
339
:
1285
–1292

[30]

Dahlof
B
, Herlitz H, Aurell M, Hansson L. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system.
Am J Hypertens
.
1992
;
5
:
900
–911

[31]

Emanueli
C
, Maestri R, Corradi D, et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice.
Circulation
.
1999
;
100
:
2359
–2365

[32]

Rosenkranz
AC
, Hood SG, Woods RL, Dusting GJ, Ritchie RH. Acute antihypertrophic actions of bradykinin in the rat heart: Importance of cyclic GMP.
Hypertension
.
2002
;
40
:
498
–503

[33]

Pfeffer
MA
, Braunwald EA, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med
.
1992
;
327
:
669
–677

[34]

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators.

N Engl J Med
.
1991
;
325
:
293
–302

[35]

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

N Engl J Med
.
2000
;
342
:
145
–153

[36]

Martorana
PA
, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist.
Eur J Pharmacol
.
1990
;
182
:
395
–396

[37]

Hartman
JC
, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.
J Cardiovasc Pharmacol
.
1993
;
21
:
996
–1003

[38]

Hoshida
S
, Yamashita N, Kawahara K, Kuzuya T, Hori M. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: Possible mechanisms.
Circulation
.
1999
;
99
:
434
–440

[39]

Vaughan
DE
. Angiotensin, fibrinolysis, and vascular homeostasis.
Am J Cardiol
.
2001
;
87
:
18
–24

[40]

Brown
NJ
, Vaughan DE. Prothrombotic effects of angiotensin.
Adv Intern Med
.
2000
;
45
:
419
–429

[41]

Labinjoh
C
, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
J Am Coll Cardiol
.
2001
;
38
:
1402
–1408

[42]

Mancini
GB
, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study.
Circulation
.
1996
;
94
:
258
–265

[43]

Minai
K
, Matsumoto T, Horie H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors.
J Am Coll Cardiol
.
2001
;
37
:
1565
–1570

[44]

Pretorius
M
, Rosenbaum DA, Vaughan DE, Brown NJ. ACE inhibition increases human vascular tPA release through endogenous bradykinin.
Circulation
.
2002
;: In Press

[45]

Vaughan
DE
, Rouleau J-L, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction.
Circulation
.
1997
;
96
:
442
–447

[46]

Wagner
A
, Herkner H, Schreiber W, et al. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.
Thromb Haemost
.
2002
;
88
:
180
–185

[47]

Brown
NJ
, Agirbasli MA, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Hypertension
.
1999
;
34
:
285
–290

[48]

Bouchie
JL
, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system.
Arterioscler Thromb Vasc Biol
.
1998
;
18
:
1771
–1779

[49]

Vanhoutte
PM
. Vascular biology. Old-timer makes a comeback.
Nature
.
1998
;
396
:
213
–216

PDF
This content is only available as a PDF.
Topic:
Issue Section:
Articles
Download all slides